Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms REWARD
- Sponsors Amgen; Celgene Corporation
- 15 Jun 2024 Results (n=99) assessing real-world use and effectiveness of apremilast for PsA presented at the 25th Annual Congress of the European League Against Rheumatism
- 12 Jun 2024 According to an Amgen media release, the company announced the presentation of data of this trial at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna.
- 13 Jul 2022 Status changed from active, no longer recruiting to completed.